Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score

Meabh McNulty, Adarsh Das, Paul Cohen, Andrew Dean

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction
Response to neoadjuvant chemotherapy is measured by CT and the decision to proceed with interval surgery is made on the radiological response after two or three cycles of therapy. The Chemotherapy Response Score grades histological tumor regression in omental metastases resected at interval surgery and is associated with progression-free survival and overall survival. It is uncertain whether radiological response is associated with prognosis and whether radiological response predicts Chemotherapy Response Score.

Objective
To assess if radiological response is associated with progression-free survival and overall survival. Additionally, to investigate whether radiological response predicts the
Chemotherapy Response Score.

Methods
Retrospective cohort study of patients with high-grade serous ovarian cancer treated with neoadjuvant chemotherapy. Radiological response was assessed by comparing CT imaging at baseline and after neoadjuvant chemotherapy using RECIST (Response Evaluation Criteria In Solid Tumors) and classified as stable disease, partial response, complete response, or progressive disease. Survival analysis was performed using Cox proportional hazard models and the log-rank test.

Results
A total of 71 patients met the inclusion criteria. Of these, 51 had pre- and post-neoadjuvant chemotherapy CT scans available for analysis. Radiological response was not associated with progression-free survival or overall survival on univariate analysis (stable disease vs partial response; HR for progression-free survival 1.15; 95% CI 0.57 to 2.32; p = 0.690; HR for overall survival 1.19; 95% CI 0.57 to 2.46; p = 0.645). In a multivariate model, radiological response was not associated with either progression-free survival (stable disease vs partial response; HR=1.19; 95% CI 0.498 to 2.85; p = 0.694) or overall survival (stable disease vs partial response; HR=0.954; 95% CI 0.38 to 2.40; p = 0.920). There was a significant association between the Chemotherapy
Response Score and radiological response (p = 0.005).

Discussion
A partial response and stable disease on radiological assessment after neoadjuvant chemotherapy in women with advanced high-grade serous ovarian cancer were not associated with survival, despite having a correlation with the Chemotherapy Response Score.
Original languageEnglish
Pages (from-to)929-934
Number of pages6
JournalInternational Journal of Gynecological Cancer
DOIs
Publication statusE-pub ahead of print - 15 May 2019

Fingerprint

Carcinoma
Drug Therapy
Disease-Free Survival
Survival
Ovarian Neoplasms
Survival Analysis
Proportional Hazards Models
Cohort Studies
Retrospective Studies
Neoplasm Metastasis
Neoplasms

Cite this

@article{3a16b61c81fd44549eacfbe27c96b0bd,
title = "Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score",
abstract = "Introduction Response to neoadjuvant chemotherapy is measured by CT and the decision to proceed with interval surgery is made on the radiological response after two or three cycles of therapy. The Chemotherapy Response Score grades histological tumor regression in omental metastases resected at interval surgery and is associated with progression-free survival and overall survival. It is uncertain whether radiological response is associated with prognosis and whether radiological response predicts Chemotherapy Response Score.ObjectiveTo assess if radiological response is associated with progression-free survival and overall survival. Additionally, to investigate whether radiological response predicts theChemotherapy Response Score.Methods Retrospective cohort study of patients with high-grade serous ovarian cancer treated with neoadjuvant chemotherapy. Radiological response was assessed by comparing CT imaging at baseline and after neoadjuvant chemotherapy using RECIST (Response Evaluation Criteria In Solid Tumors) and classified as stable disease, partial response, complete response, or progressive disease. Survival analysis was performed using Cox proportional hazard models and the log-rank test.Results A total of 71 patients met the inclusion criteria. Of these, 51 had pre- and post-neoadjuvant chemotherapy CT scans available for analysis. Radiological response was not associated with progression-free survival or overall survival on univariate analysis (stable disease vs partial response; HR for progression-free survival 1.15; 95{\%} CI 0.57 to 2.32; p = 0.690; HR for overall survival 1.19; 95{\%} CI 0.57 to 2.46; p = 0.645). In a multivariate model, radiological response was not associated with either progression-free survival (stable disease vs partial response; HR=1.19; 95{\%} CI 0.498 to 2.85; p = 0.694) or overall survival (stable disease vs partial response; HR=0.954; 95{\%} CI 0.38 to 2.40; p = 0.920). There was a significant association between the ChemotherapyResponse Score and radiological response (p = 0.005).Discussion A partial response and stable disease on radiological assessment after neoadjuvant chemotherapy in women with advanced high-grade serous ovarian cancer were not associated with survival, despite having a correlation with the Chemotherapy Response Score.",
author = "Meabh McNulty and Adarsh Das and Paul Cohen and Andrew Dean",
year = "2019",
month = "5",
day = "15",
doi = "10.1136/ijgc-2019-000222",
language = "English",
pages = "929--934",
journal = "International Journal of Gynecologic Cancer",
issn = "1048-891X",
publisher = "BMJ Specialist Journals",

}

TY - JOUR

T1 - Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma

T2 - an analysis of the correlation between CT imaging and chemotherapy response score

AU - McNulty, Meabh

AU - Das, Adarsh

AU - Cohen, Paul

AU - Dean, Andrew

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Introduction Response to neoadjuvant chemotherapy is measured by CT and the decision to proceed with interval surgery is made on the radiological response after two or three cycles of therapy. The Chemotherapy Response Score grades histological tumor regression in omental metastases resected at interval surgery and is associated with progression-free survival and overall survival. It is uncertain whether radiological response is associated with prognosis and whether radiological response predicts Chemotherapy Response Score.ObjectiveTo assess if radiological response is associated with progression-free survival and overall survival. Additionally, to investigate whether radiological response predicts theChemotherapy Response Score.Methods Retrospective cohort study of patients with high-grade serous ovarian cancer treated with neoadjuvant chemotherapy. Radiological response was assessed by comparing CT imaging at baseline and after neoadjuvant chemotherapy using RECIST (Response Evaluation Criteria In Solid Tumors) and classified as stable disease, partial response, complete response, or progressive disease. Survival analysis was performed using Cox proportional hazard models and the log-rank test.Results A total of 71 patients met the inclusion criteria. Of these, 51 had pre- and post-neoadjuvant chemotherapy CT scans available for analysis. Radiological response was not associated with progression-free survival or overall survival on univariate analysis (stable disease vs partial response; HR for progression-free survival 1.15; 95% CI 0.57 to 2.32; p = 0.690; HR for overall survival 1.19; 95% CI 0.57 to 2.46; p = 0.645). In a multivariate model, radiological response was not associated with either progression-free survival (stable disease vs partial response; HR=1.19; 95% CI 0.498 to 2.85; p = 0.694) or overall survival (stable disease vs partial response; HR=0.954; 95% CI 0.38 to 2.40; p = 0.920). There was a significant association between the ChemotherapyResponse Score and radiological response (p = 0.005).Discussion A partial response and stable disease on radiological assessment after neoadjuvant chemotherapy in women with advanced high-grade serous ovarian cancer were not associated with survival, despite having a correlation with the Chemotherapy Response Score.

AB - Introduction Response to neoadjuvant chemotherapy is measured by CT and the decision to proceed with interval surgery is made on the radiological response after two or three cycles of therapy. The Chemotherapy Response Score grades histological tumor regression in omental metastases resected at interval surgery and is associated with progression-free survival and overall survival. It is uncertain whether radiological response is associated with prognosis and whether radiological response predicts Chemotherapy Response Score.ObjectiveTo assess if radiological response is associated with progression-free survival and overall survival. Additionally, to investigate whether radiological response predicts theChemotherapy Response Score.Methods Retrospective cohort study of patients with high-grade serous ovarian cancer treated with neoadjuvant chemotherapy. Radiological response was assessed by comparing CT imaging at baseline and after neoadjuvant chemotherapy using RECIST (Response Evaluation Criteria In Solid Tumors) and classified as stable disease, partial response, complete response, or progressive disease. Survival analysis was performed using Cox proportional hazard models and the log-rank test.Results A total of 71 patients met the inclusion criteria. Of these, 51 had pre- and post-neoadjuvant chemotherapy CT scans available for analysis. Radiological response was not associated with progression-free survival or overall survival on univariate analysis (stable disease vs partial response; HR for progression-free survival 1.15; 95% CI 0.57 to 2.32; p = 0.690; HR for overall survival 1.19; 95% CI 0.57 to 2.46; p = 0.645). In a multivariate model, radiological response was not associated with either progression-free survival (stable disease vs partial response; HR=1.19; 95% CI 0.498 to 2.85; p = 0.694) or overall survival (stable disease vs partial response; HR=0.954; 95% CI 0.38 to 2.40; p = 0.920). There was a significant association between the ChemotherapyResponse Score and radiological response (p = 0.005).Discussion A partial response and stable disease on radiological assessment after neoadjuvant chemotherapy in women with advanced high-grade serous ovarian cancer were not associated with survival, despite having a correlation with the Chemotherapy Response Score.

U2 - 10.1136/ijgc-2019-000222

DO - 10.1136/ijgc-2019-000222

M3 - Article

SP - 929

EP - 934

JO - International Journal of Gynecologic Cancer

JF - International Journal of Gynecologic Cancer

SN - 1048-891X

ER -